Reactive oxygen species

JCRI-ABTS and USMI Reports Statistically Significant Results of the Canady Helios Cold Plasma Phase 1 Clinical Trial on Patients with Stage 4 and Recurrent Advanced Solid Tumors

Retrieved on: 
Thursday, June 15, 2023
Other Health, Research, General Health, Oncology, Medical Devices, Clinical Trials, Science, Surgery, Biotechnology, Alternative Medicine, FDA, Health, Anoxic waters, DNA, Radiation, IRE, Cell death, RNS, Safety, CAP, Survival, Cancer, Ovary, Breast, Global health, Reactive nitrogen species, Human embryonic stem cells clinical trials, Prostate, Treatment of lung cancer, Immunotherapy, CHCP, Messenger, Glioblastoma, ASCO, Irreversible electroporation, ROS, Sarcoma, SMC, Clinical trial, LRR, Patient, Risk, Melanoma, Sheba Medical Center, Plasma, Annual general meeting, Education minister, IDE, Rush University Medical Center, RUMC, Reactive oxygen species, Society, Medical imaging

(ClinicalTrials.gov identifier: NCT04267575)

Key Points: 
  • (ClinicalTrials.gov identifier: NCT04267575)
    Cancer remains a significant global health challenge, with over 1.9 million new cases and 608,570 cancer-related fatalities in the United States in 2021.
  • USMI’s Canady Helios Cold Plasma (CHCP) system, a non-thermal (26-30°C) and non-contact Cold Atmospheric Plasma (CAP) jet, offers a promising solution.
  • Twenty patients ranging from 26-85 years of age undergoing surgery for advanced stage 4 or recurrent solid tumors were enrolled.
  • Patients with preoperative treatments such as neoadjuvant chemotherapy, immunotherapy, radiation, and previous surgery were eligible.

Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency

Retrieved on: 
Thursday, May 25, 2023
Advanz Pharma, Sorbitol dehydrogenase, Central nervous system, Journal, European Medicines Agency, ATP, Medicine, Cell, Doctor of Philosophy, CNS, Brain cell, Drosophila, EMA, ROS, HIV disease progression rates, Patient, Reactive oxygen species, Sorbitol, Therapy, Adenosine triphosphate, Disease, Pharmaceutical industry, Galactosemia, EU, SORD

Additionally, the Company announced that new data has been published in the Journal of Clinical Investigation on govorestat treatment in models of SORD Deficiency.

Key Points: 
  • Additionally, the Company announced that new data has been published in the Journal of Clinical Investigation on govorestat treatment in models of SORD Deficiency.
  • Applied Therapeutics has partnered govorestat for treatment of SORD Deficiency as well as Galactosemia in Europe with ADVANZ Pharma.
  • The new data on govorestat treatment in models of SORD Deficiency was recently published in the Journal of Clinical Investigation.
  • These findings uncover the molecular and cellular pathophysiology of sorbitol toxicity in SORD neuropathy, and govorestat provides a potential treatment strategy for patients with SORD Deficiency.

SonALAsense Welcomes Dr. Ely Benaim as Chief Medical Officer and Executive Vice President of Development

Retrieved on: 
Tuesday, May 9, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Data management, Amgen, Drug development, Diffuse intrinsic pontine glioma, Jude the Apostle, History, Doctor of Philosophy, Glioblastoma, High-intensity focused ultrasound, DIPG, Journal, Patient, ALA, Reactive oxygen species, Takeda Oncology, Journal of Neuro-Oncology, Decompression (diving), Sonodynamic therapy, Aminolevulinic acid, FDA, SDT, Safety, Medical imaging, Nursing, Pharmaceutical industry, Medical device, Development

SonALAsense, a pioneer in the development of non-invasive Sonodynamic Therapy (SDT) using SONALA-001 in combination with Insightec’s MR-guided focused ultrasound (MRgFUS), has appointed Ely Benaim, M.D., as Chief Medical Officer and Executive Vice President of Development.

Key Points: 
  • SonALAsense, a pioneer in the development of non-invasive Sonodynamic Therapy (SDT) using SONALA-001 in combination with Insightec’s MR-guided focused ultrasound (MRgFUS), has appointed Ely Benaim, M.D., as Chief Medical Officer and Executive Vice President of Development.
  • Benaim brings decades of clinical and industry experience and incredible insights to SonALAsense,” said Mark de Souza, PhD, Chief Executive Officer at SonALAsense.
  • Later, he moved into drug development, taking high-profile positions at Amgen, Sangamo BioSciences, Millennium Pharmaceuticals, Rexahn Pharmaceuticals and others.
  • Prior to joining SonALAsense, he was Chief Medical Officer for Novocure, where he managed several pivotal clinical trials.

Bold Therapeutics to Present Best-in-Class Phase 2 Metastatic Colorectal Cancer Data at AACR 2023

Retrieved on: 
Thursday, April 13, 2023
DNA, Clinician Administered PTSD Scale, AACR, Cell death, Therapy, Unfolded protein response, Progression-free survival, Safety, American Association for Cancer Research, Multimedia, Large intestine, PFS, ASCO, Plasma, ROS, DNA repair, FOLFOX, Reactive oxygen species, Cancer, Clutch (eggs), UPR, Induced cell cycle arrest, IL-27, GRP78, ORR, Pharmaceutical industry, Online shopping, Patient

VANCOUVER, B.C., April 13, 2023 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced that it will present two posters – a clinical poster (#CT149) and a translational research poster (#2259) – at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 14 - 19, 2023 in Orlando, Florida.

Key Points: 
  • VANCOUVER, B.C., April 13, 2023 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced that it will present two posters – a clinical poster (#CT149) and a translational research poster (#2259) – at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 14 - 19, 2023 in Orlando, Florida.
  • "This robustly positive interim clinical data is a testament to the hard work and dedication of our team, our collaborators, clinical sites, investigators and patients.
  • Previous Phase 1b trial results, presented at ASCO 2022, demonstrated that BOLD-100 in combination with FOLFOX was generally safe and well-tolerated.
  • Additional Phase 2 safety and efficacy results in advanced gastric and bile duct cancer have been accepted for presentation at ASCO 2023 in June.

Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure

Retrieved on: 
Tuesday, March 7, 2023
Research, TSX, Therapy, Cardiomyopathy, PPAR, Heart failure, Calcium, American College of Cardiology, Pericarditis, Patient, American College, Inflammation, Translation, Cannabidiol, Heart, Myocarditis, Development, CRDL, Reactive oxygen species, ARCHER, World Heart Federation, Dietary supplement, Pharmaceutical industry, Fibrosis, Hypertrophy

Oakville, Ontario--(Newsfile Corp. - March 7, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced study results from one of its international collaborating research centers demonstrating that its pharmaceutically manufactured cannabidiol significantly prevents cardiac dysfunction and the development of fibrosis and cardiomyocyte hypertrophy in a pre-clinical model of heart failure and reduces expression of key inflammatory and fibrotic markers. Cannabidiol is the active pharmaceutical ingredient in CardiolRx™, the Company's lead investigational oral drug candidate currently in Phase II clinical trials for recurrent pericarditis and acute myocarditis, and in its novel subcutaneously administered drug formulation intended for use in heart failure and currently in pre-clinical development.

Key Points: 
  • TecSalud is one of the Company's international collaborating research centers working towards the common goal of developing therapies to advance the treatment of heart diseases.
  • The poster entitled "Cannabidiol Therapy for Chronic Heart Failure Prevents Cardiac Pathological Remodeling in a Non-ischemic Cardiomyopathy Murine Model" was presented on March 4th within the "Heart Failure and Cardiomyopathies: Basic and Translational Science 1" session of ACC.2023/WCC.
  • This work builds upon existing knowledge by confirming cannabidiol's cardioprotective properties and, in this model, its ability to reduce inflammation and prevent hypertrophy and fibrosis in heart tissue.
  • This poster presented data related to the role of cannabidiol in mitochondrial calcium dynamics in hypertrophic cells.

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib’s Mechanisms of Action at the AACR Targeting RAS Conference

Retrieved on: 
Tuesday, March 7, 2023
Trigger, Protein, Mitosis, Growth, Cell division, Reactive oxygen species, ROS, Cancer, Lung cancer, FDA, Poster, NLRP3, Therapy, RAS, Conference, AACR, NQO2, Microtubule, Patient, KRAS, JNK, Vaccine, Pharmaceutical industry

NEWTOWN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced new preclinical data characterizing rigosertib’s mechanisms of action in a poster at the American Association for Cancer Research Special Conference on Targeting RAS (AACR Targeting RAS Conference).

Key Points: 
  • “The preclinical results presented at the Targeting RAS Conference increase our understanding of rigosertib’s anti-cancer effects and thereby represent a valuable tool to inform its continued clinical development,” said Mark Gelder, M.D., Chief Medical Officer of Onconova.
  • “I am particularly encouraged by data showing rigosertib-induced activation of the NLRP3 inflammasome.
  • Additional data identified the proteins NQO2, ERO1A, and NEK7 as potential novel targets that may be modulated by rigosertib.
  • Activation of NQO2 and/or ERO1A leads to reactive oxygen species (ROS)-induced activation of JNK signaling, which in-turn leads to RAS-MAPK pathway inhibition.

Researchers Discover How Too Much Oxygen Damages Cells and Tissues

Retrieved on: 
Wednesday, March 8, 2023
Genome, MD, Protein, Biochemistry, University of California, San Francisco, Gene, SAN, UCSF, Oxygen, Plant, Goldilocks and the Three Bears, Gladstone Institutes, Cell, Enzyme, Obstructive sleep apnea, Reactive oxygen species, CRISPR, Growth, Death, Animal, Non-Euclidean geometry, Molecular Cell, Bacteria, Hyperoxia, DNA, Sulfur, Tissue, Iron, Patient, Hari Krishan Jain, Human, Baek, Stroke, End organ damage, Sleep apnea, Doctor of Philosophy, Seizure, Splenic infarction, Nursing, Pharmaceutical industry, Phosphorus

SAN FRANCISCO, March 8, 2023 /PRNewswire/ -- When it comes to oxygen, you can have too much of a good thing. Breathing air that contains higher levels of oxygen than the usual 21 percent found in Earth's atmosphere can cause organ damage, seizures, and even death in people and animals, particularly if it's in excess of the body's oxygen needs. Until now, however, scientists have mostly speculated about the mechanisms behind this phenomenon, known as oxygen toxicity, or hyperoxia.

Key Points: 
  • Now, researchers at Gladstone Institutes have discovered how excess oxygen changes a handful of proteins in our cells that contain iron and sulfur—a chemical process similar to the rusting of iron.
  • While clinicians have long studied the details of how oxygen shortage impacts cells and tissues (for example, in heart attacks and strokes), the effects of excess oxygen have been relatively understudied.
  • As a result, cells stop functioning correctly and consume even less oxygen, causing a further increase in oxygen levels in the surrounding tissues.
  • "One important takeaway is that hyperoxia is not impacting cells and tissues solely through reactive oxygen species, as many had assumed," says Jain.

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

Retrieved on: 
Tuesday, February 21, 2023
Accident, Brain, Glasgow Coma Scale, Excitotoxicity, Tropomyosin receptor kinase B, Messenger, Human, Trial of the century, TBI, BDNF, AGN, Patient, DMT, Traumatic brain injury, Stroke, Vehicle registration plates of Nepal, N,N-Dimethyltryptamine, CSE, Reactive oxygen species, Nursing, Pharmaceutical industry

AGN Neuro has an active stroke research program underway and is currently conducting a Phase 1 DMT study in the Netherlands at the Centre for Human Drug Research.

Key Points: 
  • AGN Neuro has an active stroke research program underway and is currently conducting a Phase 1 DMT study in the Netherlands at the Centre for Human Drug Research.
  • AGN Neuro, in consultation with its TBI advisors, may plan and conduct certain preclinical research to help better guide the planned Phase 2 clinical study.
  • DMT is an agonist of sigma-1, a part of the body’s natural defense against physiological stresses, which is elevated following TBI.
  • AGN Neuro is also pleased to announce that it has appointed global TBI expert Dr. Andrew Maas as a scientific and medical advisor to help guide its TBI research program.

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

Retrieved on: 
Tuesday, January 31, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, NAFLD, NR, Brain, Syndrome, Radical, KTH, Trial of the century, PD, CMA, Neuron, Hyperaemia, Regulatory affairs, Royal institute, Royal Society Te Apārangi, Translational Neurodegeneration, Patient, NAC, Clinical trial, Liver, Cell, Ageing, Molecular Systems Biology, Oxidative stress, Research, Science for Life Laboratory, Neurodegenerative disease, Science, Risk, ChromaDex, Death, Mitochondrion, ScienceDirect, Systems biology, AD, Serine, COVID-19, Advanced Science, Fatty liver disease, Necrosis, Reactive oxygen species, Dietary supplement, Medical device, Placebo

This study marks a milestone as it is the first-ever peer-reviewed clinical study to investigate the effects of CMA supplementation in human AD patients.

Key Points: 
  • This study marks a milestone as it is the first-ever peer-reviewed clinical study to investigate the effects of CMA supplementation in human AD patients.
  • In a preclinical study, AD and Parkinson’s disease (PD) rat models were used to demonstrate CMA supplementation resulted in improved brain and liver metabolism.
  • “The promising results showcased that activation of mitochondria with the administration of CMA led to improved cognitive functions in AD patients,” Dr. Mardinoglu remarked.
  • “Further research to determine if CMA improves metabolic abnormalities and cognitive functions in AD patients is warranted and we look forward to initiating a Phase 3 study in the near future.”

Innova Market Insights: Supplements for skin health nearly tripled from 2017 to 2021

Retrieved on: 
Monday, February 6, 2023
Innova, Carbon, Capsule, DNA, Microalgae, Biophysical environment, Water, Cosmeceutical, Skin care, Solar energy, Electricity, Marketing, ROS, Maintenance, CO2, Oxidative stress, Sunlight, Skin, Astaxanthin, Research, Food, Temperature, LED, UV, Beauty, Radiation, Immune system, Growth, Hyperpigmentation, Carbon footprint, Dietary supplement, Reactive oxygen species, Elasticity, Tablet, Cosmetics

KIBBUTZ KETURA, Israel, Feb. 6, 2023 /PRNewswire/ -- Supplements targeting skin health is booming, reports Innova Market Insights. The category experienced more than 30% average annual growth in product launches of dietary supplements globally between 2017 and 2021. Europe was the leading region with the most nutricosmetic supplement launches at 41% in that period, while North America had 32% of supplement launches. Then, the pandemic hit. Botanical & herbal supplements for beauty from within have seen the biggest growth, supplement launches were five times more in 2021 than in 2017. The top formats used for skin health supplements are capsules and tablets while gummy skin health supplements are fast trending.

Key Points: 
  • The category experienced more than 30% average annual growth in product launches of dietary supplements globally between 2017 and 2021.
  • Botanical & herbal supplements for beauty from within have seen the biggest growth, supplement launches were five times more in 2021 than in 2017.
  • The top formats used for skin health supplements are capsules and tablets while gummy skin health supplements are fast trending.
  • Innova reports that the leading category for astaxanthin product launches in the last five years is skin health (followed by eye health and brain health).